APUS

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -1.80
Percentage change -45.00	%

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.11	Insider Own	-	Shs Outstand	11.70M	Perf Week	-
Market Cap	25.74M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Income	-1.39M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-0.12	P/B	-	EPS next Y	-	ROA	-638.88%	Short Interest	-	Perf Year	-
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	-	52W Range	- - -	Perf YTD	-
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-	Beta	-
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-	ATR (14)	1.96
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-82.06%	Oper. Margin	-	RSI (14)	-	Volatility	- -
Employees	2	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	40.49%	Payout	-	Rel Volume	-	Prev Close	4.00
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	-	Price	2.20
SMA20	0.00%	SMA50	0.00%	SMA200	0.00%	Trades		Volume	1,664,403	Change	-45.00%

May-08-25 05:00PM

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

(GlobeNewswire)

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your FINVIZ experience